$1.7B Humira IP Verdict Won't Get Supreme Court Review
The U.S. Supreme Court on Tuesday declined to review a Federal Circuit ruling that negated a $1.67 billion patent verdict against Abbott Laboratories, refusing to consider a Johnson & Johnson unit's...To view the full article, register now.
Already a subscriber? Click here to view full article